Transgene S.A.
TRGNF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $5 | $0 | $0 | $3 |
| % Growth | 1,512.3% | 1,134.8% | -99.3% | – |
| Cost of Goods Sold | $18 | -$15 | $15 | $14 |
| Gross Profit | -$13 | $16 | -$15 | -$11 |
| % Margin | -291.1% | 5,530.6% | -66,956.5% | -346.9% |
| R&D Expenses | $18 | $19 | $15 | $17 |
| G&A Expenses | $4 | -$5 | $5 | $4 |
| SG&A Expenses | $4 | -$5 | $5 | $4 |
| Sales & Mktg Exp. | $0 | $0 | -$0 | $0 |
| Other Operating Expenses | -$18 | $17 | -$16 | -$17 |
| Operating Expenses | $4 | $32 | $4 | $4 |
| Operating Income | -$17 | -$16 | -$20 | -$15 |
| % Margin | -372.6% | -5,573.6% | -86,213% | -469% |
| Other Income/Exp. Net | -$2 | $2 | $0 | $8 |
| Pre-Tax Income | -$19 | -$14 | -$20 | -$6 |
| Tax Expense | $0 | $3 | -$3 | $0 |
| Net Income | -$19 | -$17 | -$16 | -$6 |
| % Margin | -421.4% | -6,157% | -71,673.9% | -204.8% |
| EPS | -0.15 | -0.18 | -0.16 | -0.063 |
| % Growth | 16.7% | -12.5% | -152.4% | – |
| EPS Diluted | -0.15 | -0.18 | -0.16 | -0.063 |
| Weighted Avg Shares Out | 129 | 101 | 101 | 101 |
| Weighted Avg Shares Out Dil | 133 | 101 | 101 | 101 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $8 |
| Interest Expense | $1 | -$1 | $1 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$16 | -$8 | -$19 | -$13 |
| % Margin | -358.4% | -2,854.9% | -80,626.1% | -429.2% |